BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32622736)

  • 21. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
    El Hachem G; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):81-92. PubMed ID: 33054442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
    Eiger D; Wagner M; Pondé NF; Nogueira MS; Buisseret L; de Azambuja E
    Acta Oncol; 2020 Jun; 59(6):723-725. PubMed ID: 32167397
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
    Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
    Bøttcher TM; Cold S; Jensen AB
    Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
    Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
    Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
    Takahashi K; Uozumi R; Mukohara T; Hayashida T; Iwabe M; Iihara H; Kusuhara-Mamishin K; Kitagawa Y; Tsuchiya M; Kitahora M; Nagayama A; Kosaka S; Asano-Niwa Y; Seki T; Ohnuki K; Suzuki A; Ono F; Futamura M; Kawazoe H; Nakamura T
    Oncologist; 2024 Jun; 29(6):e741-e749. PubMed ID: 38340010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
    Lee KA; Shepherd ST; Johnston SR
    Future Oncol; 2019 Oct; 15(29):3309-3326. PubMed ID: 31464525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.